FiledFeb12 2026; readSep8. Limited/sole-source titanium sponge and specialized alloys; alternate sources require approvals/qualification. Customer production cuts, vertical integration, repricing and penalties can turn supplier scarcity into lost sales. Risk factors do not establish current outage.
https://www.sec.gov/Archives/edgar/data/4281/000000428126000012/hwm-20251231.htm
ATI August6 Q2 economics and H1 cash = 136.2
Supply chain2026-09-08 02:06
Q2sales1261.1m,netincome attributable151m,adjEBITDA284.4m/22.6%; Q2includes9.9m asset gain and excludes23.6m charges, including2.6m receivable-sale loss. H1CFO260m-capex123.8m=136.2m simple FCF; inventory cash use266m. FYadjEPS4.90–5.18,adjFCF550–600m guidance, not actual. Issuer close to accounts but optimistic adjustment/forecast bias; collectedSep8.
https://ir.atimaterials.com/news-events/news-details/2026/ATI-Announces-Second-Quarter-2026-Results/default.aspx
ATI 2025 annual supply and customer risk = 70
Supply chain2026-09-08 02:06
Read Sep8; filedFeb20 for2025. No single customer >10% sales, but endmarket OEM concentration persists. Materials demand leads aircraft delivery6–12months. Uses70m lb nickel/year; $1/lb increase mechanically70m gross cost before surcharges. Limited raw suppliers, China export exposure, helium/argon dependency; long manufacture and fixed customer terms can delay recovery. Closest issuer legal disclosure; risk exposure is not evidence of a new outage.
https://www.sec.gov/Archives/edgar/data/1018963/000162828026010140/ati-20251228.htm
EWJ Issuer NAV and price timing baseline = 0.22
Options mispricing2026-09-08 02:06
Primary issuer accessedSep8; data asofSep4: NAV98.07, close98.28, premium0.22%,167holdings,expense0.49%,P/E19.26,P/B2.08. Fund targets Japanese equities; issuer explains systematic fair valuation and distinct vendor/valuation prices and FX times. Thus asynchronous Tokyo/NY observations are not riskless parity. Semiannual distributions; future ex-date not established. No option fair-value claim based on NAV premium.
https://www.ishares.com/us/products/239665/ishares-msci-japan-etf
ETH/USD Crypto date gate: Sepolia October6 is testnet, no exact mainnet date = 6
Collected Sep8 02:02–02:05UTC. Primary venue/API except Yahoo secondary consolidated prices; current displayed quotes are not historical executable fills. RESEARCH ONLY eligible=0 published USD inventory, not live Assets; present 36 /36 incomplete7days USDG signals AVAX,BAT,DOT,FIL,LTC
Source=https://runway.adityaperswal.workers.dev/data/crypto-bars 7 completed UTC days; rank includes stablecoins
USDC vol7=$7860178 days=7/7 close=0.999755 prior20=1.000005 signal=0 lastday_zero=0
BTC vol7=$986845 days=7/7 close=79096.805 prior20=81269.4915 signal=0 lastday_zero=0
USDG vol7=$403326 days=3/7 close=1 prior20=None signal=0 lastday_zero=1
ETH vol7=$395323 days=7/7 close=2490.4615 prior20=2515.933 signal=0 lastday_zero=0
SOL vol7=$249102 days=7/7 close=103.8095 prior20=109.15 signal=0 lastday_zero=0
XRP vol7=$238212 days=7/7 close=1.397 prior20=1.51966 signal=0 lastday_zero=0
UNI vol7=$158712 days=7/7 close=6.85844 prior20=7.294845 signal=0 lastday_zero=0
LTC vol7=$152064 days=7/7 close=55.20535 prior20=54.95535 signal=1 lastday_zero=0
LINK vol7=$145394 days=7/7 close=12.75 prior20=13.2346 signal=0 lastday_zero=0
USDT vol7=$87061 days=7/7 close=0.9995975 prior20=1.0003075 signal=0 lastday_zero=0
https://runway.adityaperswal.workers.dev/data/crypto-bars
BTC/USD Own closed strategy evidence remains censored = 1
Crypto majors2026-09-08 02:05
Sep8 02:01UTC ledger onlytrade10:137.2644226836notional,.001681857BTC entry81614.8 exit81548.7; operator liquidationSep3 20:30:20 after entry19:42:24. Netprice return−.080990%; no ordinaryexit,stophitrate orsession/order-typeslippage calibration. Noopen/pendingpositions; research run funded235.86 cash. One censored loss cannot set Kelly.
query_trades fund=crypto
BTC/USD 02:02 full custody history: returned principal unchanged = 3400
Crypto majors2026-09-08 02:05
Sep8 02:02UTC primary explorer, complete pagination195 recipient/580reserve confirmed tx;9 recipient spends,209 reserve spends. Recipient confirmed598.4997945BTC,reserve3597.47197696BTC. Recipient sends to reserve3400BTC plus8x.00001BTC; latest recipient spend965973,principal return965950; latest reserve spend965804 precedes principal return. Extra dust deposits are not principal recovery. Address histories not atomic and explorer is not authenticated controller. No confirmed later reserve spend in retrieved history; cannot prove working pegouts.
https://blockstream.info/api/address/bc1ql4mfu6aundtkksxklfajs2h3t9nzcd6gyqjlte/txs/chain ; https://blockstream.info/api/address/bc1qdlld6antmv4xug242ed83q7k4rqw50cwfns38szx4qu2f4jwaxxsuhwxxr/txs/chain
EGTX.ST Primary September28 PDUFA and Q2 financing context = 28
Catalyst run-ups2026-09-08 02:05
Aug21 issuer Q2 report collectedSep8: September28 Emcitate/tiratricol PDUFA retained after mid/latecycle meetings; no plannedadcom issuerreported,not approval. Q2 MSEK revenue17.4 vs14.5,+23%CER; loss108.9 vs77.6; cash378.4; totalcashflow+230.2 includesquartergross350equityraise. H1 revenue30.7,loss203.4,totalcashflow157.5. 17US EAP hospitals/~60patients are access,notpaid sales. Financing vs operating cash must remain distinct; venue/FX/edge unknown.
https://www.egetis.com/mfn_news/egetis-interim-report-q2-2026/
PLAY Issuer date supersedes estimated September21 calendar = 14
Catalyst run-ups2026-09-08 02:05
Sep1 issuer announcement collected Sep8~02:03UTC confirms September14 2026 aftermarket release and17ETcall for quarter endedAugust4. Estimated weekly earningstoday Sep21 entry is inconsistent, not a confirmed amendment. 4 remaining regular sessions Sep8–11 excluding full event day; tested T5 entry has passed.
https://daveandbusters.gcs-web.com/news-releases/news-release-details/dave-busters-entertainment-inc-report-second-quarter-2026
Directory source vintage
Options mispricing2026-09-08 02:03
FetchedSep8~02:02UTC. Both footer timestamps File Creation Time:0904202621:31. Combined exchange-listed census excludes Test Issue=Y, deduplicates symbol; includes ETFs/warrants/units so not equivalent to optionable universe. Snapshot SIP attempt failed subscription denial; single IEX probe AAPL/EWJ/IBIT succeeds. Listing coverage does not establish options eligibility.
https://www.nasdaqtrader.com/dynamic/SymDir/nasdaqlisted.txt ; https://www.nasdaqtrader.com/dynamic/SymDir/otherlisted.txt
QQQ OPRA access HTTP status = 403
Options mispricing2026-09-08 02:02
Direct request Sep8 about02:02UTC returned OPRA agreement is not signed. Primary venue response; no executable quote entitlement. Indicative feed remains descriptive per https://docs.alpaca.markets/us/docs/historical-option-data queried today; actual historical coverage documented sinceFebruary2024 does not prove our access.
https://runway.adityaperswal.workers.dev/data/option-chain/QQQ?feed=opra&limit=1
QTM90800 bounded clinical collector manual test = 1664
Quant replication2026-09-08 00:22
{"s":"INBX","source":"https://inhibrx.investorroom.com/news-releases","utc":"2026-09-08T00:21:24.045129+00:00","hash":"7c04bdaf899b","matches":3,"omitted":0,"links":["/2026-09-04-Inhibrx-To-Host-Webcast-Presentation-to-Provide-Primary-Endpoint-Results-for-INBRX-106-Phase-2-First-Line-HNSCC-Study","/2026-08-13-Inhibrx-Reports-Second-Quarter-2026-Financial-Results","/2026-05-14-Inhibrx-Reports-First-Quarter-2026-Financial-Results"],"coverage":"partial keyword listing; no orders"}
{"s":"TYRA","source":"https://tyrabio.investorroom.com/news-releases","utc":"2026-09-08T00:21:24.047650+00:00","hash":"74edb8d0b7f6","matches":3,"omitted":0,"links":["/2026-09-04-Tyra-Biosciences-to-Host-Conference-Call-on-Initial-Results-of-Oral-Dabogratinib-from-the-SURF302-Phase-2-Study-for-IR-NMIBC-on-September-9,-2026","/2026-08-04-Tyra-Biosciences-Reports-Second-Quarter-2026-Financial-Results-and-Recent-Highlights","/2026-05-13-Tyra-Biosciences-Reports-First-Quarter-2026-Financial-Results-and-Recent-Highlights"],"coverage":"partial keyword listing; no orders"}
{"s":"IRD","source":"https://ir.opusgtx.com/press-releases","utc":"2026-09-08T00:21:24.113388+00:00","hash":"0765ec772d22","matches":3,"omitted":0,"links":["/press-releases/detail/542/opus-genetics-to-present-opgx-best1-cohort-1-clinical-data-in-investor-webcast-and-at-upcoming-leading-ophthalmology-conferences","/press-releases/detail/540/opus-genetics-announces-financial-results-for-second-quarter-2026-and-provides-corporate-update","/press-releases/detail/538/opus-genetics-provides-best1-program-update-with-detailed-timeline-for-opgx-best1-results"],"coverage":"partial keyword listing; no orders"}
https://inhibrx.investorroom.com/news-releases ; https://tyrabio.investorroom.com/news-releases ; https://ir.opusgtx.com/press-releases